265 related articles for article (PubMed ID: 10764786)
1. The p53 tumor suppressor stimulates the catalytic activity of human topoisomerase IIalpha by enhancing the rate of ATP hydrolysis.
Kwon Y; Shin BS; Chung IK
J Biol Chem; 2000 Jun; 275(24):18503-10. PubMed ID: 10764786
[TBL] [Abstract][Full Text] [Related]
2. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
3. Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIalpha and beta in various human cancer cell lines.
Hochhauser D; Valkov NI; Gump JL; Wei I; O'Hare C; Hartley J; Fan J; Bertino JR; Banerjee D; Sullivan DM
J Cell Biochem; 1999 Nov; 75(2):245-57. PubMed ID: 10502297
[TBL] [Abstract][Full Text] [Related]
4. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
5. HMGB1 interacts with human topoisomerase IIalpha and stimulates its catalytic activity.
Stros M; Bacíková A; Polanská E; Stokrová J; Strauss F
Nucleic Acids Res; 2007; 35(15):5001-13. PubMed ID: 17636313
[TBL] [Abstract][Full Text] [Related]
6. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
[TBL] [Abstract][Full Text] [Related]
7. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
[TBL] [Abstract][Full Text] [Related]
9. Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage.
Fortune JM; Osheroff N
J Biol Chem; 1998 Jul; 273(28):17643-50. PubMed ID: 9651360
[TBL] [Abstract][Full Text] [Related]
10. Communication between the ATPase and cleavage/religation domains of human topoisomerase IIalpha.
Bjergbaek L; Kingma P; Nielsen IS; Wang Y; Westergaard O; Osheroff N; Andersen AH
J Biol Chem; 2000 Apr; 275(17):13041-8. PubMed ID: 10777608
[TBL] [Abstract][Full Text] [Related]
11. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
[TBL] [Abstract][Full Text] [Related]
12. Novel xanthone-polyamine conjugates as catalytic inhibitors of human topoisomerase IIα.
Minniti E; Byl JAW; Riccardi L; Sissi C; Rosini M; De Vivo M; Minarini A; Osheroff N
Bioorg Med Chem Lett; 2017 Oct; 27(20):4687-4693. PubMed ID: 28919339
[TBL] [Abstract][Full Text] [Related]
13. Degradation of topoisomerase IIalpha during adenovirus E1A-induced apoptosis is mediated by the activation of the ubiquitin proteolysis system.
Nakajima T; Morita K; Ohi N; Arai T; Nozaki N; Kikuchi A; Osaka F; Yamao F; Oda K
J Biol Chem; 1996 Oct; 271(40):24842-9. PubMed ID: 8798759
[TBL] [Abstract][Full Text] [Related]
14. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
15. The catalytic activities of DNA topoisomerase II are most closely associated with the DNA cleavage/religation steps.
Scala D; Escargueil AE; Couprie J; Larsen AK
Biochimie; 1999 Jul; 81(7):771-9. PubMed ID: 10492025
[TBL] [Abstract][Full Text] [Related]
16. Examination of the Impact of Copper(II) α-(N)-Heterocyclic Thiosemicarbazone Complexes on DNA Topoisomerase IIα.
Wilson JT; Jiang X; McGill BC; Lisic EC; Deweese JE
Chem Res Toxicol; 2016 Apr; 29(4):649-58. PubMed ID: 26982206
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase C delta activates topoisomerase IIalpha to induce apoptotic cell death in response to DNA damage.
Yoshida K; Yamaguchi T; Shinagawa H; Taira N; Nakayama KI; Miki Y
Mol Cell Biol; 2006 May; 26(9):3414-31. PubMed ID: 16611985
[TBL] [Abstract][Full Text] [Related]
18. HU-331 is a catalytic inhibitor of topoisomerase IIα.
Regal KM; Mercer SL; Deweese JE
Chem Res Toxicol; 2014 Dec; 27(12):2044-51. PubMed ID: 25409338
[TBL] [Abstract][Full Text] [Related]
19. The DNA dependence of the ATPase activity of human DNA topoisomerase IIalpha.
Hammonds TR; Maxwell A
J Biol Chem; 1997 Dec; 272(51):32696-703. PubMed ID: 9405488
[TBL] [Abstract][Full Text] [Related]
20. Two-Mechanism Model for the Interaction of Etoposide Quinone with Topoisomerase IIα.
Gibson EG; King MM; Mercer SL; Deweese JE
Chem Res Toxicol; 2016 Sep; 29(9):1541-8. PubMed ID: 27533850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
